Regeneron Pharmaceuticals Inc (REGN) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
Regeneron Pharmaceuticals Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Regeneron Pharmaceuticals Inc's ROI in the third quarter of 2026? Regeneron Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 13 % in its third quarter of 2026, which is below Regeneron Pharmaceuticals Inc's average return on investment, which stands at 17.5%.
ROI has improved compared to 11.83% in the second quarter of 2026, due to net income growth.
Within the Healthcare sector 40 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 647, from total ROI ranking in the second quarter of 2026 at 700.
In recent groundbreaking news, the European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of odronextamab for the treatment of relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). This recommendation comes after extensive analysis of the Phase 1 and pivotal Phase 2 clinical trials, which showcased remarkable response rates and durable outcomes for patients with these challenging malignancies. The recommendation is based on compelling evidence from the trials, demonstrating the robust and durable response rates of odronextamab in patients with relapsed/refractory FL and DLBCL. These lymphomas are known to pose significant challenges to conventional treatment approaches, and the availability of a novel therapy like odronextamab brings new hope to patients worldwide.
Regeneron Faces Regulatory Hurdles for Odronextamab, Potential Treatment for Lymphomas TARRYTOWN, N.Y., March 25, 2024 - Pharmaceutical company Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has provided an update on its Biologics License Application (BLA) for odronextamab, a potential treatment for relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL). The U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) regarding the application, citing the enrollment status of the confirmatory trials as the only issue. However, the CRLs did not raise any concerns regarding the drug s clinical efficacy, safety, trial design, labeling, or manufacturing. Regeneron is a leading pharmaceutical company known for its innovative therapies and research in the field of biotechnology. The company has been actively developing odronextamab as a potential breakthrough therapy for R/R FL and R/R DLBCL, two types of lymphomas that currently lack effective treatment options.
Financial Statements
Regeneron Pharmaceuticals Inc's III. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
